Brokers Offer Predictions for AbbVie FY2026 Earnings

AbbVie Inc. (NYSE:ABBV - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for AbbVie in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst C. Gould anticipates that the company will post earnings per share of $14.12 for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $210.00 target price on the stock. The consensus estimate for AbbVie's current full-year earnings is $12.31 per share.

AbbVie (NYSE:ABBV - Get Free Report) last posted its earnings results on Friday, April 25th. The company reported $2.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.40 by $0.06. The firm had revenue of $13.34 billion for the quarter, compared to analyst estimates of $12.91 billion. AbbVie had a return on equity of 296.28% and a net margin of 7.59%. AbbVie's revenue was up 8.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.31 EPS.

A number of other brokerages also recently commented on ABBV. BNP Paribas upgraded shares of AbbVie to a "hold" rating in a report on Thursday, May 8th. Erste Group Bank upgraded AbbVie to a "strong-buy" rating in a report on Monday, March 17th. Wells Fargo & Company boosted their price objective on shares of AbbVie from $210.00 to $240.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Citigroup reaffirmed a "neutral" rating and issued a $205.00 price objective (down previously from $210.00) on shares of AbbVie in a research report on Wednesday, May 14th. Finally, Evercore ISI raised their target price on AbbVie from $204.00 to $205.00 and gave the company an "outperform" rating in a research note on Monday, April 28th. Eight equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $211.29.

AbbVie Price Performance

AbbVie stock traded up $0.15 during midday trading on Tuesday, reaching $189.31. 4,086,840 shares of the company were exchanged, compared to its average volume of 6,226,250. The firm's 50-day simple moving average is $183.92 and its 200-day simple moving average is $187.28. AbbVie has a 1 year low of $163.52 and a 1 year high of $218.66. The company has a market capitalization of $334.40 billion, a price-to-earnings ratio of 78.88, a P/E/G ratio of 1.62 and a beta of 0.50. The company has a debt-to-equity ratio of 17.94, a quick ratio of 0.55 and a current ratio of 0.66.

Institutional Investors Weigh In On AbbVie

Several hedge funds have recently modified their holdings of ABBV. TD Capital Management LLC increased its position in shares of AbbVie by 82.9% in the first quarter. TD Capital Management LLC now owns 128 shares of the company's stock worth $27,000 after acquiring an additional 58 shares in the last quarter. EnRich Financial Partners LLC boosted its stake in AbbVie by 196.4% in the 4th quarter. EnRich Financial Partners LLC now owns 166 shares of the company's stock worth $29,000 after purchasing an additional 110 shares during the period. Promus Capital LLC purchased a new position in AbbVie during the 4th quarter worth approximately $30,000. Abound Financial LLC acquired a new stake in AbbVie during the 1st quarter valued at $30,000. Finally, Bradley & Co. Private Wealth Management LLC purchased a new stake in shares of AbbVie in the fourth quarter valued at $31,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at AbbVie

In other news, EVP Jeffrey Ryan Stewart sold 58,832 shares of the stock in a transaction on Monday, March 31st. The stock was sold at an average price of $210.08, for a total transaction of $12,359,426.56. Following the completion of the sale, the executive vice president now owns 53,234 shares in the company, valued at approximately $11,183,398.72. This represents a 52.50% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.25% of the company's stock.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.